[Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
D000328:Adult; D000368:Aged; D001201:Ascites / Q000188:drug therapy*; D002191:Canrenoic Acid / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004487:Edema / Q000188:drug therapy*; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes / Q000627:therapeutic use*; D014883:Water-Electrolyte Imbalance / Q000188:drug therapy*
D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D005665:Furosemide; D002191:Canrenoic Acid; D004976:Ethacrynic Acid
Saggio terapeutico di un antialdosteronico iniettabile (K-canrenoato) in stati di ritenzione idro-salina